In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ocular Therapeutix Inc. (NASDAQ:OCUL) reported that Svlsf V, Llc. has picked up 1,605,207 of common stock as of 2017-02-07.
The acquisition brings the aggregate amount owned by Svlsf V, Llc. to a total of 1,605,207 representing a 6.5% stake in the company.
For those not familiar with the company, Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company’s product pipeline includes marketed candidate ReSure Sealant and products under development, such as OTX-DP, OTX-TP, OTX-MP and anti-VEGF hydrogel depot. The Company’s lead product candidates are OTX-DP and OTX-TP. The OTX-DP product candidate incorporates the corticosteroid dexamethasone as an active pharmaceutical ingredient in its punctum plug.
A glance at Ocular Therapeutix Inc. (NASDAQ:OCUL)’s key stats reveals a current market capitalization of 198.42 million based on 28.76 million shares outstanding and a price at last close of $6.89 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-12-15, Sawhney picked up 45,300 at a purchase price of $7.85. This brings their total holding to 677,390 as of the date of the filing.
On the sell side, the most recent transaction saw Fortune unload 9,470 shares at a sale price of $17.16. This brings their total holding to 112,060.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Ocular Therapeutix Inc. (NASDAQ:OCUL) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
